EUVIMEDEUVIMED entdecken
Open Access

Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML

Courtney D DiNardo iD, Jennifer Marvin-Peek iD, Sanam Loghavi, Koichi Takahashi iD, Ghayas C Issa iD, Wei-Ying Jen iD, Naval G Daver iD, Patrick K Reville iD, Nicholas J Short iD, Koji Sasaki iD, Jillian K Mullin, Corey A Bradley und 17 weitere

Journal of Clinical Oncology · 20.08.2025 · 43 (24) · 2692-2699

DOI: 10.1200/jco-25-00640 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.08.2025. Verfasst von Courtney D DiNardo und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Sulfonamides, Leukemia, Myeloid, Acute, Bridged Bicyclo Compounds, Heterocyclic. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The development of targeted therapeutics has revolutionized treatment for elderly patients with AML. Two doublet regimens are approved in the frontline setting for intensive chemotherapy (IC)–ineligible AML: venetoclax (VEN) in combination with hypomethylating agent (HMA) therapy and azacitidine (AZA) plus ivosidenib (IVO) specifically for IDH1 -mutated AML. Although both regimens have improved AML outcomes, most patients will either not respond to frontline therapy or relapse, with dismal salvage outcomes. METHODS We herein report on 60 newly diagnosed IC-ineligible patients treated at our institution with triplet regimens for isocitrate dehydrogenase ( IDH )–mutant AML. Patients received either AZA + VEN + IVO on NCT03471260 ( IDH1 -mutated patients only) or oral decitabine + VEN + IVO/enasidenib on NCT04774393 (arms for IDH1- and IDH2 -mutant disease, respectively). RESULTS The triplet regimens were well tolerated with low early mortality (n = 1 [2%] in 60 days) and a similar safety profile to HMA + VEN and isocitrate dehydrogenase inhibitor doublet regimens. The composite complete remission rate (CRc) was 92% (55/60), with an overall response rate of 95% (57/60). With a median follow-up of 27.4 months, the median overall survival (OS) has not yet been reached. The 2-year OS was 69% with a 2-year cumulative incidence of relapse of 24%. Patients with treated-secondary AML (tsAML) experienced inferior outcomes with a CRc of 71% (12/17) and a 2-year OS of 34%; the 2-year OS was 84% in patients without tsAML. Nineteen patients (32%) transitioned to stem cell transplant, and 51% remain on study. CONCLUSION Given the excellent outcomes of IDH-triplet therapy for newly diagnosed, IC-ineligible IDH -mutant AML, further prospective studies comparing IDH-triplet versus IDH-doublet regimens are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Isocitrate DehydrogenaseSulfonamidesLeukemia, Myeloid, AcuteBridged Bicyclo Compounds, HeterocyclicAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleAgedMaleMiddle AgedMutationAged, 80 and overGlycineAzacitidineDecitabineTriazinesAminopyridinesAdultPyridines

Substanzen

Isocitrate DehydrogenasevenetoclaxSulfonamidesBridged Bicyclo Compounds, HeterocyclicivosidenibGlycineAzacitidineIDH1 protein, humanDecitabineTriazines

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Bronx, New York.

ORCID-Profile: Courtney D DiNardo, Jennifer Marvin-Peek, Koichi Takahashi, Ghayas C Issa, Wei-Ying Jen, Naval G Daver, Patrick K Reville, Nicholas J Short, Koji Sasaki, Gautam Borthakur, Abhishek Maiti, Yesid Alvarado, Naveen Pemmaraju, Hussein A Abbas, Danielle E Hammond, Fadi Haddad, Kelly S Chien, Steven M Kornblau, Elias Jabbour, Farhad Ravandi, Tapan Kadia, Guillermo Garcia-Manero, Marina Y Konopleva, Hagop M Kantarjian

Förderung

  • NCI NIH HHS

Zitieren

APA

DiNardo, C. D., Marvin-Peek, J., Loghavi, S., Takahashi, K., Issa, G. C., Jen, W. Y., Daver, N. G., Reville, P. K., Short, N. J., Sasaki, K., Mullin, J. K., Bradley, C. A., Borthakur, G., Maiti, A., Alvarado, Y., Pemmaraju, N., Abbas, H. A., Hammond, D. E., Haddad, F., …, & Kantarjian, H. M. (2025). Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML. Journal of Clinical Oncology, 43(24), 2692-2699. https://doi.org/10.1200/jco-25-00640

Vancouver

DiNardo CD, Marvin-Peek J, Loghavi S, Takahashi K, Issa GC, Jen WY, et al. Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML. Journal of Clinical Oncology. 2025;43(24):2692-2699. doi:10.1200/jco-25-00640

BibTeX
@article{DiNardo2025,
  author = {DiNardo, Courtney D and Marvin-Peek, Jennifer and Loghavi, Sanam and Takahashi, Koichi and Issa, Ghayas C and Jen, Wei-Ying and Daver, Naval G and Reville, Patrick K and Short, Nicholas J and Sasaki, Koji and Mullin, Jillian K and Bradley, Corey A and Borthakur, Gautam and Maiti, Abhishek and Alvarado, Yesid and Pemmaraju, Naveen and Abbas, Hussein A and Hammond, Danielle E and Haddad, Fadi and Bravo, Guillermo Montalban and Chien, Kelly S and Yilmaz, Musa and Kornblau, Steven M and Jabbour, Elias and Ravandi, Farhad and Kadia, Tapan and Garcia-Manero, Guillermo and Konopleva, Marina Y and Kantarjian, Hagop M},
  title = {Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {24},
  pages = {2692--2699},
  doi = {10.1200/jco-25-00640}
}
Kostenlos starten →